{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:03:17Z","timestamp":1790614997637,"version":"4.1.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1681\/asn.2011040340","type":"journal-article","created":{"date-parts":[[2012,2,17]],"date-time":"2012-02-17T00:07:32Z","timestamp":1329437252000},"page":"842-853","source":"Crossref","is-referenced-by-count":85,"title":["Dose-Dependent Effects of Sirolimus on mTOR Signaling and Polycystic Kidney Disease"],"prefix":"10.1681","volume":"23","author":[{"given":"Zlata","family":"Novalic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke M.","family":"van der Wal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter N.","family":"Leonhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Koehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn H.","family":"Breuning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward K.","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"de Heer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien J.M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20230208","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMra022161","article-title":"Polycystic kidney disease.","volume":"350","author":"Wilson","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-14-20230208","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/hmg\/9.18.2743","article-title":"Polycystin-1, the product of the polycystic kidney disease 1 gene, co-localizes with desmosomes in MDCK cells.","volume":"9","author":"Scheffers","year":"2000","journal-title":"Hum Mol Genet"},{"key":"R3-14-20230208","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ng1076","article-title":"Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells.","volume":"33","author":"Nauli","year":"2003","journal-title":"Nat Genet"},{"key":"R4-14-20230208","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/path.2392","article-title":"Tight junction composition is altered in the epithelium of polycystic kidneys.","volume":"216","author":"Yu","year":"2008","journal-title":"J Pathol"},{"key":"R5-14-20230208","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cell.2009.08.045","article-title":"Polycystin-1 and -2 dosage regulates pressure sensing.","volume":"139","author":"Sharif-Naeini","year":"2009","journal-title":"Cell"},{"key":"R6-14-20230208","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int"},{"key":"R7-14-20230208","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1074\/jbc.273.11.6013","article-title":"The polycystic kidney disease 1 gene product mediates protein kinase C alpha-dependent and c-Jun N-terminal kinase-dependent activation of the transcription factor AP-1.","volume":"273","author":"Arnould","year":"1998","journal-title":"J Biol Chem"},{"key":"R8-14-20230208","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0092-8674(02)00716-X","article-title":"PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2.","volume":"109","author":"Bhunia","year":"2002","journal-title":"Cell"},{"key":"R9-14-20230208","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1681\/ASN.2005050534","article-title":"Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase\/Akt signaling pathway.","volume":"17","author":"Boca","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R10-14-20230208","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"R11-14-20230208","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/path.2734","article-title":"Elevated TGFbeta-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease.","volume":"222","author":"Hassane","year":"2010","journal-title":"J Pathol"},{"key":"R12-14-20230208","doi-asserted-by":"crossref","first-page":"F1193","DOI":"10.1152\/ajprenal.00419.2010","article-title":"Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: In vivo evidence from a Pkd1-deletion model.","volume":"300","author":"Leonhard","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"R13-14-20230208","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: The last 3 years.","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"key":"R14-14-20230208","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: A randomized, double-blind, placebo-controlled trial.","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"R15-14-20230208","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R16-14-20230208","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD.","volume":"21","author":"Perico","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R17-14-20230208","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease.","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"R18-14-20230208","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"R20-14-20230208","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism.","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"R21-14-20230208","doi-asserted-by":"crossref","first-page":"F1597","DOI":"10.1152\/ajprenal.00430.2009","article-title":"Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.","volume":"297","author":"Wu","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"R22-14-20230208","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.","volume":"16","author":"Tao","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R23-14-20230208","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1093\/ndt\/gfp129","article-title":"Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).","volume":"24","author":"Zafar","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R24-14-20230208","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.transproceed.2009.06.097","article-title":"Mammalian target of rapamycin and autosomal dominant polycystic kidney disease.","volume":"41","author":"W\u00fcthrich","year":"2009","journal-title":"Transplant Proc"},{"key":"R25-14-20230208","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1093\/hmg\/ddh336","article-title":"Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease.","volume":"13","author":"Lantinga-van Leeuwen","year":"2004","journal-title":"Hum Mol Genet"},{"key":"R26-14-20230208","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1093\/hmg\/ddm299","article-title":"Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice.","volume":"16","author":"Lantinga-van Leeuwen","year":"2007","journal-title":"Hum Mol Genet"},{"key":"R27-14-20230208","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/MCB.01259-08","article-title":"Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1.","volume":"29","author":"Distefano","year":"2009","journal-title":"Mol Cell Biol"},{"key":"R28-14-20230208","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1681\/ASN.2009101070","article-title":"Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD.","volume":"21","author":"Vujic","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R29-14-20230208","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes.","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R30-14-20230208","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.","volume":"21","author":"Shillingford","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R31-14-20230208","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/ki.2010.250","article-title":"Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.","volume":"78","author":"Zafar","year":"2010","journal-title":"Kidney Int"},{"key":"R32-14-20230208","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients.","volume":"19","author":"Qian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R33-14-20230208","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1165\/rcmb.2007-0055OC","article-title":"Steroid and oxygen effects on eIF4F complex, mTOR, and ENaC translation in fetal lung epithelia.","volume":"37","author":"Otulakowski","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R34-14-20230208","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/lt.21804","article-title":"Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways.","volume":"15","author":"Bridle","year":"2009","journal-title":"Liver Transpl"},{"key":"R35-14-20230208","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.pharmthera.2009.03.014","article-title":"Therapeutic role of sirolimus in non-transplant kidney disease.","volume":"123","author":"Rangan","year":"2009","journal-title":"Pharmacol Ther"},{"key":"R36-14-20230208","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/ijc.25097","article-title":"Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis.","volume":"127","author":"de Gruijl","year":"2010","journal-title":"Int J Cancer"},{"key":"R37-14-20230208","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","article-title":"Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?","volume":"10","author":"Canaud","year":"2010","journal-title":"Am J Transplant"},{"key":"R38-14-20230208","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","article-title":"mTOR and cancer: Many loops in one pathway.","volume":"22","author":"Efeyan","year":"2010","journal-title":"Curr Opin Cell Biol"},{"key":"R39-14-20230208","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/dvg.20207","article-title":"Transgenic mice expressing tamoxifen-inducible Cre for somatic gene modification in renal epithelial cells.","volume":"44","author":"Lantinga-van Leeuwen","year":"2006","journal-title":"Genesis"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201205000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:21:34Z","timestamp":1786130494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201205000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2011040340","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}